Relay Therapeutics, Inc. (RLAY)
Healthcare
- Fundamental
- 3
- Sentiment
- 3
- Technical
- 4
Buy limit: RLAY is pulling back within an intact uptrend (price above SMA20/50/200, MACD 0.29/0.08 > 0 and expanding, dollar volume confirming); a GTC limit at 19.60 under the 19.64/19.69 two-session low shelf with the stop at 18.45 (1.0x ATR floor, beneath the 18.71 swing low) targets 21.90 then 23.63 for 2.00 R/R.
Company overview
Relay Therapeutics, Inc. is a precision medicine company focused on developing small molecule therapies for cancer and genetic conditions. Its pipeline includes drug candidates like RLY-4008, RLY-2608, and RLY-1971, targeting specific molecular pathways. The company collaborates with D. E. Shaw Research and Genentech to advance its drug discovery efforts.
Fundamental
fairRelay Therapeutics is well-funded but remains speculative due to negative operating economics and reliance on pipeline success.
Relay Therapeutics is a clinical-stage biotech with a strong cash runway but deeply negative operating economics. The SEC 10-Q filed 2026-08-06 reports $910.93M of cash and marketable securities at 2026-06-30, net operating cash outflow of $105.22M for the first six months of 2026, and a stated runway into 2029, with no material interest-bearing debt disclosed. Against that, revenue remains small ($15.36M in FY2025) and losses/cash burn are large (FY2025 net loss $276.48M; trailing free cash flow about -$212.21M), making traditional valuation ratios unreliable and producing negative DCF outputs. Upside relies mainly on clinical/regulatory catalysts and comes with dilution risk, reinforced by an expanded ~$462.98M ATM equity program.
Sentiment
fairRecent catalysts have improved sentiment, but the absence of near-term drivers keeps it mixed.
Dominant catalysts: FDA approval of Relay-originated Lyrfigtu on 2026-09-24 (regulator_confirmed) and the 2026-09-22 ReDiscover-2 Phase 3 initiation for zovegalisib (announced) — both trailing but only partially priced — against a mildly positive primary-tier tape and a determinate mild delta improvement (baseline ≈ −0.02 mixed → scoring ≈ +0.12). Red-Flag Screen clean with no cap applied; no forward-dated driver, a consolidating tape and silent retail hold the read at a constructive mixed setup.
Technical
goodThe stock is consolidating within an uptrend, supported by a positive MACD cross and confirming volume.
Uptrend intact: price 19.72 sits above SMA20 18.35, SMA50 18.40, SMA200 15.43, EMA9 18.98 and EMA21 18.58, while MACD crossed above its signal on 11-09 and is now positive and expanding (line 0.29, signal 0.08, histogram +0.22). RSI 56.9 and Williams %R -27.9 remain short of overbought, and volume confirms the advance (11-06 +8.5% on 3.2M shares and 11-09 +6.9% on 3.8M shares versus 2.4M/1.9M on the two pullback days; 20-day dollar volume $47.2M). One weak signal: ADX 15.5 shows only modest trend strength and the stock is short-term extended (+16% in five sessions), so the plan buys a dip to the two-session low shelf rather than chasing. Score 4.
You’re looking at 2026-11-11 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

